Can our bodies be trained to destroy cancer cells? CAR-T therapies have undoubtedly garnered significant attention and investment over the past several years even with the risks and development challenges that scientists continue to face. In the BioHealth Capital Region, gene therapy companies are rapidly emerging making the District of Columbia and its’ surrounding area a new hub for gene therapy. Through external partnership, Janssen R&D is jointly working to develop solutions in the gene therapy and CAR-T space.
The bewildering pace of change in this field poses challenges for regulators and providers in selecting the right CAR-T products for the right patients at the right time. Johnson & Johnson Innovation, JLABS has gathered thought leaders and innovators in the field to share the exciting research and technologies they are advancing and insights on what the future could look like for the area of immuno-oncology.
As Regional Head of JLABS @ Washington, DC, Sally sets the strategic direction and oversees all operational activities for JLABS in the greater Washington metro region, including Maryland and Virginia. In this role, Sally is responsible for the process of evaluating and selecting a strong portfolio of innovators for JLABS @ Washington, DC, and building strategic partnerships with corporate, academic, government and industry organizations that aim to strengthen the region’s life sciences innovation network.
Dr. Kalayoglu is co-founder and CEO of Cartesian Therapeutics, a fully-integrated, clinical stage biopharmaceutical company developing novel cell and gene therapies to treat cancer and autoimmune diseases. Prior to Cartesian, he was co-founder and CEO of Topokine, which he led from concept to late-stage clinical trials, followed by a successful sale to Allergan (NYSE:AGN). Dr. Kalayoglu is a board-certified ophthalmologist who completed his residency and research fellowship at Harvard, MD/PhD in immunology at the University of Wisconsin-Madison, and MBA from the MIT Sloan School of Management.
Jeff Galvin is the CEO and Founder of American Gene Technologies™ (AGT). He earned his BA degree in Economics from Harvard in 1981 and has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Following his startup experience, he retired to become an Angel Investor in real estate and high tech. He came out of retirement to found and fund AGT after meeting Roscoe Brady at NIH.
Currently serving as the research site head for Kite Santa Monica. Chris received his Ph.D. Biochemistry from the University of Washington in 2000. Chris has worked biotech in pharma for over 18 years including Genentech, Oncomed, Juno Therapeutics and Celgene. Chris has extensive experience in the discovery and development of adoptive cell therapies, monoclonal antibodies, as well as cellular engineering. He is an inventor on 6 patents and has published numerous papers in the fields of protein structure and engineering, immunology, and oncology.
Johnson & Johnson Innovation – JLABS Notice
The views expressed during this event, including during any associated networking and/or individual meetings by anyone other than an employee of Johnson & Johnson Innovation LLC, its parent company or any affiliate companies (herein after referred to as “JJI”) are those of the speakers or experts alone, and such experts or speakers are solely responsible for the information and opinions expressed by them. By hosting this event, the presentations and any associated networking and/or individual meetings, JJI does not endorse the views of the speakers, experts or the attendees, and JJI makes no warranties, express or implied, as to the content, the views, advice or the information
